NCT06408584招募中不适用
Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab in Patients With Region-relapsed or Progressive Esophageal Squamous Cell Carcinoma: a Single Arm, Observational Study
Anhui Provincial Hospital1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2024年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signing informed consent; ECOG 0-2 points;
- •Age over 18 years old, gender is not limited;
- •Esophageal squamous cell carcinoma confirmed by pathology or clinically diagnosed by imaging;
- •Recurrence of the tumor area after radical surgery or radical chemoradiotherapy; Regional progression of advanced esophageal squamous cell carcinoma after first-line or second-line treatment;
- •Clinical staging: regional recurrence (rT0-4N0-3M0-1a) or regional progression (cT0-4N0-3M0-1) (AJCC/UICC esophageal cancer staging (8th edition));
- •Tumor lesions can be evaluated;
- •Expected survival ≥3 months;
- •Major organ function is normal, meeting the following criteria: (i) blood routine examination A.HB ≥90g/L; b.ANC≥1.5×109/L; C. PLT ≥80×109/L; (ii) Biochemical examination: a. ALT/AST≤2.5ULN; b. TBIL≤1.5ULN; c. Plasma Cr≤1.5ULN or creatinine clearance (CCr)≥60ml/min;
- •Women of childbearing age must have had a pregnancy within 7 days before starting treatment and the result is negative;
- •All enrolled patients should take adequate contraceptive measures throughout the treatment period and 4 weeks after completion;
- •no serious hematopoietic function, heart function, endocrine and immune function defects;
- •No patients with grade 3 or above other serious medical diseases.
排除标准
- •Under 18 years of age; ECOG is greater than 2;
- •The diagnosis of esophageal cancer is not supported by pathological biopsy or image examination;
- •Salvage surgery was performed after tumor recurrence;
- •The patient has any active autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism; The patient had vitiligo; Those with complete remission of asthma in childhood can be included without any intervention in adulthood; Patients with asthma requiring medical intervention with bronchodilators are not included);
- •Patients who were taking immunosuppressants or systemic hormone therapy for immunosuppressive purposes (doses >10mg/ day of prednisone or other therapeutic hormones) and continued to use within 2 weeks before enrollment;
- •Patients with severe and/or uncontrolled concomitant disease of grade 3 or higher, including: poor blood pressure control, myocardial ischemia or myocardial infarction, arrhythmia, active or uncontrolled severe infection; Liver diseases such as decompensated liver disease, active hepatitis B (HBV-DNA≥104 copy numbers /ml or 2000IU/ml), or hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower detection limit of analytical methods);
- •Pregnant or lactating women;
- •Patients who have a history of psychotropic drug abuse and cannot quit or have mental disorders;
- •Patients who have participated in clinical trials of other drugs within four weeks; .Patients or family members refused to participate in the study.
结局指标
主要结局
PFS
时间窗: 1 month post treatment]
progression free survival
次要结局
- ORR(1 month post treatment])
- 1，3-year overall survival, Adverse effect(1 month post treatment])
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Hypofractionated Accelerated Radiotherapy for Low Risk Localized Prostate CancerProstate CancerNCT01578902Sunnybrook Health Sciences Centre84
招募中
不适用
Hypofractionated Radiotherapy for Thymic Epithelial TumorsThymoma and Thymic CarcinomaThymic CancerThymic Epithelial TumorThymomaNCT06692062Rongrong Zhou100
招募中
不适用
Radical Hypofractionated Radiotherapy for Localized Prostate CancerLocalized Prostate CancerNCT06325774Changhai Hospital20
Unknown
1 期
Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate CancerProstate CancerNCT01505075Sunnybrook Health Sciences Centre30
已完成
2 期
Hypofractionated Radiotherapy Followed by Hypo-boost for Local Advanced NSCLCNon-small Cell Lung CancerNCT03900117Sun Yat-sen University77